The sale volume is immaterial relative to market cap and follows non-cash stock grants, indicating routine tax or diversification activity. No bearish read-through. Monitor upcoming SEC filings for any material corporate developments.
QURE drugs
QURE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 15 $27.87entry
- T+1 · 5mo ago −3.16%α −2.56% · $26.99
- T+5 · 5mo ago +59.28%α +60.66% · $44.39
- T+20 · 4mo ago +47.47%α +48.22% · $41.10
- T+60 · 2mo ago +65.05%α +64.05% · $46.00
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Four uniQure directors sold a total of 7,972 shares for approximately $215,722 on June 11, 2026, all at $27.06 per share. The prior day, each director received non-cash stock grants; the sales represent a trivial 0.013% of the company's $1.7 billion market cap and are routine portfolio adjustments, not a bearish signal.
Key Financial Metrics
Key Facts
- Four directors (Post, Kaye, Jacques, Balachandran) each sold 1,993 shares on June 11, 2026.
- Total sale value: approximately $215,722 (0.013% of $1.7B market cap).
- Each director received 21,530 non-cash stock grants on June 10, 2026 (13,980 + 7,550 shares at $0).
- No C-suite executives participated in any trades.
Financial Impact
Four directors sold an aggregate of 7,972 shares for $215,722.18, representing approximately 0.013% of the company's $1.7B market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QURE-1781300363664 |
Track record
38 reports on QURE
6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.
Filters
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
- Nov 4, 202612d ago 8-K Bullish 7/10 No price data
- Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
- Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
- Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
- Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
- Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
- Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
- Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers